Haem.io

Explainable Diagnostic Intelligence

AML and MDS classification built for genomic-era haematology, aligned to WHO 2022, ICC 2022, and ELN decision logic.

Try the AML/MDS Classifier Read Methodology

100% Gene Accuracy

WHO + ICC 2022

ELN Risk Aligned

See It in Action

Watch Dr. Luke Carter-Brzezinski demonstrate Haem.io classifying a real AML case in minutes

How Haem.io Works

A simple three-step diagnostic workflow

Extract

Pull key findings from reports into a clean structured profile.

LLM-powered extraction from free-text haematology reports. Identifies mutations, cytogenetics, blast counts, and flow cytometry markers with 100% gene detection accuracy.

Classify

Apply WHO, ICC, and ELN logic to produce a traceable result.

Dual-framework classification against WHO 2022 5th Edition and ICC 2022. Every decision node is traceable with full reasoning chains visible.

Act

Support next-step decisions with diagnosis, risk, and rationale.

Generates ELN 2022 risk for AML, IPSS-M/R for MDS. Provides rationale and evidence for clinical decision support alongside treatment considerations.

Core Capabilities

Focused on classification, risk, and transparent reasoning.

Dual Classification

Simultaneous evaluation against both WHO 2022 and ICC 2022 guidelines ensures comprehensive diagnostic coverage.

Risk Stratification

Automated calculation of ELN 2022 (AML) and IPSS-M/R (MDS) risk scores for immediate prognostic insight.

Transparent Logic

Every diagnostic decision is traceable to specific evidence and guideline criteria. No black boxes.

Data Extraction

LLM-powered extraction from free-text reports with 100% gene detection accuracy for TP53, CEBPA, and more.

NHS-Ready Deployment

TRE-compatible air-gapped mode. No data leaves the network. Deployable within secure NHS environments.

Gene Extraction Accuracy

Classification Frameworks

Faster with Parallel Processing

<0min

Report to Diagnosis

Built on Clinical Standards

Every classification decision maps directly to published guideline criteria.

WHO 2022

5th Edition

World Health Organization Classification of Haematolymphoid Tumours

ICC 2022

International Consensus

International Consensus Classification of Myeloid Neoplasms and Acute Leukaemias

ELN 2022

Risk Stratification

European LeukemiaNet Recommendations for Diagnosis and Management of AML

Dual-framework classification ensures comprehensive coverage across both major international standards, with automated risk scoring aligned to current evidence-based guidelines.

Ready to modernise your diagnostic workflow?

Try the interactive AML/MDS classifier — no login required.

Launch Classifier Sign In to App